Drug Profile

Zalsupindole - Delix Therapeutics

Alternative Names: AAZ; DLX-001; DLX-1

Latest Information Update: 04 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Delix Therapeutics
Class Antidepressants; Neuropsychotherapeutics; Small molecules
Mechanism of Action Serotonin 2A receptor partial agonists; Serotonin 2B receptor antagonists; Serotonin 2C receptor partial agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I CNS disorders; Major depressive disorder

Most Recent Events

29 Oct 2025 Delix Therapeutics received FDA clearance for initiation of a phase II trial for Major depressive disorder
29 Oct 2025 Efficacy data from a phase I study released by Delix Therapeutics
29 Oct 2025 Delix Therapeutics plans to initiate a phase II trial for Major depressive disorder

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com